Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia

被引:184
作者
Lugthart, Sanne
Groschel, Stefan
Beverloo, H. Berna
Kayser, Sabine
Valk, Peter J. M.
van Zelderen-Bhola, Shama Lydia
Ossenkoppele, Gert Jan
Vellenga, Edo
van den Berg-de Ruiter, Eva
Schanz, Urs
Verhoef, Gregor
Vandenberghe, Peter
Ferrant, Augustin
Kohne, Claus-Henning
Pfreundschuh, Michael
Horst, Heinz A.
Koller, Elisabeth
von Lilienfeld-Toal, Marie
Bentz, Martin
Ganser, Arnold
Schlegelberger, Brigitte
Jotterand, Martine
Krauter, Jurgen
Pabst, Thomas
Theobald, Matthias
Schlenk, Richard F.
Delwel, Ruud
Dohner, Konstanze
Lowenberg, Bob
Doehner, Hartmut [1 ]
机构
[1] Univ Hosp, Dept Internal Med 3, Ulm, Germany
关键词
BONE-MARROW-TRANSPLANTATION; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; ADULT PATIENTS; CYTOGENETIC ABNORMALITIES; POSTREMISSION THERAPY; NORMAL-TISSUES; EXPRESSION; DIAGNOSIS; CANCER;
D O I
10.1200/JCO.2010.29.2771
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Acute myeloid leukemia (AML) with inv(3)(q21q26.2)/t(3; 3)(q21; q26.2) inv(3)/t(3; 3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3; 3) remain largely unresolved. Patients and Methods Cytogenetics, molecular genetics, therapy response, and outcome analysis were performed in 6,515 newly diagnosed adult AML patients. Patients were treated on Dutch-Belgian HematoOncology Cooperative Group/Swiss Group for Clinical Cancer Research (HOVON/SAKK; n = 3,501) and German-Austrian Acute Myeloid Leukemia Study Group (AMLSG; n = 3,014) protocols. EVI1 and MDS1/EVI1 expression was determined by real-time quantitative polymerase chain reaction. Results 3q abnormalities were detected in 4.4% of AML patients (288 of 6,515). Four distinct groups were defined: A: inv(3)/t(3; 3), 32%; B: balanced t(3q26), 18%; C: balanced t(3q21), 7%; and D: other 3q abnormalities, 43%. Monosomy 7 was the most common additional aberration in groups (A), 66%; (B), 31%; and (D), 37%. N-RAS mutations and dissociate EVI1 versus MDS1/EVI1 overexpression were associated with inv(3)/t(3; 3). Patients with inv(3)/t(3; 3) and balanced t(3q21) at diagnosis presented with higher WBC and platelet counts. In multivariable analysis, only inv(3)/t(3; 3), but not t(3q26) and t(3q21), predicted reduced relapse-free survival (hazard ratio [HR], 1.99; P<.001) and overall survival (HR, 1.4; P=.006). This adverse prognostic impact of inv(3)/t(3; 3) was enhanced by additional monosomy 7. Group D 3q aberrant AML also had a poor outcome related to the coexistence of complex and/or monosomal karyotypes and cryptic inv(3)/t(3; 3). Conclusion Various categories of 3q abnormalities in AML can be distinguished according to their clinical, hematologic, and genetic features. AML with inv(3)/t(3; 3) represents a distinctive subgroup with unfavorable prognosis.
引用
收藏
页码:3890 / 3898
页数:9
相关论文
共 39 条
[1]   Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission:: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial [J].
Breems, DA ;
Boogaerts, MA ;
Dekker, AW ;
Van Putten, WLJ ;
Sonneveld, P ;
Huijgens, PC ;
Van der Lelie, J ;
Vellenga, E ;
Gratwohl, A ;
Verhoef, GEG ;
Verdonck, LF ;
Löwenberg, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (01) :59-65
[2]   Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype [J].
Breems, Dimitri A. ;
Van Putten, Wim L. J. ;
De Greef, Georgine E. ;
Van Zelderen-Bhola, Shama L. ;
Gerssen-Schoorl, Klasien B. J. ;
Mellink, Clemens H. M. ;
Nieuwint, Aggie ;
Jotterand, Martine ;
Hagemeijer, Anne ;
Beverloo, H. Berna ;
Lowenberg, Bob .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4791-4797
[3]   Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].
Byrd, JC ;
Mrózek, K ;
Dodge, RK ;
Carroll, AJ ;
Edwards, CG ;
Arthur, DC ;
Pettenati, MJ ;
Patil, SR ;
Rao, KW ;
Watson, MS ;
Koduru, PRK ;
Moore, JO ;
Stone, RM ;
Mayer, RJ ;
Feldman, EJ ;
Davey, FR ;
Schiffer, CA ;
Larson, RA ;
Bloomfield, CD .
BLOOD, 2002, 100 (13) :4325-4336
[4]  
Charrin Christiane, 2002, Hematol J, V3, P21, DOI 10.1038/sj.thj.6200143
[5]   REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA [J].
CHESON, BD ;
CASSILETH, PA ;
HEAD, DR ;
SCHIFFER, CA ;
BENNETT, JM ;
BLOOMFIELD, CD ;
BRUNNING, R ;
GALE, RP ;
GREVER, MR ;
KEATING, MJ ;
SAWITSKY, A ;
STASS, S ;
WEINSTEIN, H ;
WOODS, WG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :813-819
[6]   Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].
Cheson, BD ;
Bennett, JM ;
Kopecky, KJ ;
Büchner, T ;
Willman, CL ;
Estey, EH ;
Schiffer, CA ;
Döhner, H ;
Tallman, MS ;
Lister, TA ;
LoCocco, F ;
Willemze, R ;
Biondi, A ;
Hiddemann, W ;
Larson, RA ;
Löwenberg, B ;
Sanz, MA ;
Head, DR ;
Ohno, R ;
Bloomfield, CD .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649
[7]   Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].
Doehner, Hartmut ;
Estey, Elihu H. ;
Amadori, Sergio ;
Appelbaum, Frederick R. ;
Buechner, Thomas ;
Burnett, Alan K. ;
Dombret, Herve ;
Fenaux, Pierre ;
Grimwade, David ;
Larson, Richard A. ;
Lo-Coco, Francesco ;
Naoe, Tomoki ;
Niederwieser, Dietger ;
Ossenkoppele, Gert J. ;
Sanz, Miguel A. ;
Sierra, Jorge ;
Tallman, Martin S. ;
Loewenberg, Bob ;
Bloomfield, Clara D. .
BLOOD, 2010, 115 (03) :453-474
[8]   Acute myeloid leukaemia [J].
Estey, Elihu ;
Doehner, Hartmut .
LANCET, 2006, 368 (9550) :1894-1907
[9]   Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family [J].
Fears, S ;
Mathieu, C ;
ZeleznikLe, N ;
Huang, S ;
Rowley, JD ;
Nucifora, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (04) :1642-1647
[10]  
GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515